The DOI matches its Crossref record; 113 of the 113 references it cites were found in a registry or an index.
Impact of a five-dimensional framework on R&D productivity at AstraZeneca
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success
Lovering, F., Bikker, J., & Humblet, C. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901241e · Cited by 4,495
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Bhatia, S. N., & Ingber, D. E. (2014) · Nature Biotechnology · doi:10.1038/nbt.2989 · Cited by 3,305
Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay
Molina, D. M., Jafari, R., Ignatushchenko, M., Seki, T., Larsson, E. A., Dan, C., Sreekumar, L., Cao, Y., & Nordlund, P. (2013) · Science · doi:10.1126/science.1233606 · Cited by 2,261
Cross, D. A. E., Ashton, S. E., Ghiorghiu, S., Eberlein, C., Nebhan, C. A., Spitzler, P. J., Orme, J. P., Finlay, M. R. V., Ward, R. A., Mellor, M. J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0337 · Cited by 2,246
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
Mateo, J., Carreira, S., Sandhu, S., Miranda, S., Mossop, H., Perez-Lopez, R., Nava Rodrigues, D., Robinson, D., Omlin, A., Tunariu, N., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506859 · Cited by 2,185
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
Jänne, P. A., Yang, J. C.-H., Kim, D.-W., Planchard, D., Ohe, Y., Ramalingam, S. S., Ahn, M.-J., Kim, S.-W., Su, W.-C., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411817 · Cited by 2,116
A TALE nuclease architecture for efficient genome editing
Miller, J. C., Tan, S., Qiao, G., Barlow, K. A., Wang, J., Xia, D. F., Meng, X., Paschon, D. E., Leung, E., Hinkley, S. J., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1755 · Cited by 2,098
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
Diagnosing the decline in pharmaceutical R&D efficiency
Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3681 · Cited by 1,981
How were new medicines discovered?
Swinney, D. C., & Anthony, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3480 · Cited by 1,812
The support of human genetic evidence for approved drug indications
Nelson, M. R., Tipney, H., Painter, J. L., Shen, J., Nicoletti, P., Shen, Y., Floratos, A., Sham, P. C., Li, M. J., Wang, J., et al. (2015) · Nature Genetics · doi:10.1038/ng.3314 · Cited by 1,666
Thress, K. S., Paweletz, C. P., Felip, E., Cho, B. C., Stetson, D., Dougherty, B., Lai, Z., Markovets, A., Vivancos, A., Kuang, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3854 · Cited by 1,589
Self-citationInduced protein degradation: an emerging drug discovery paradigm
Lai, A. C., & Crews, C. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.211 · Cited by 1,486
The exploration of macrocycles for drug discovery — an underexploited structural class
Driggers, E. M., Hale, S. P., Lee, J., & Terrett, N. K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2590 · Cited by 1,370
Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., & Pangalos, M. N. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4309 · Cited by 1,344
Self-citationHirsch, F. R., McElhinny, A., Stanforth, D., Ranger-Moore, J., Jansson, M., Kulangara, K., Richardson, W., Towne, P., Hanks, D., Vennapusa, B., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.11.2228 · Cited by 1,270
The chemical evolution of oligonucleotide therapies of clinical utility
Khvorova, A., & Watts, J. K. (2017) · Nature Biotechnology · doi:10.1038/nbt.3765 · Cited by 1,216
Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults
Steingart, K. R., Schiller, I., Horne, D. J., Pai, M., Boehme, C. C., & Dendukuri, N. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009593.pub3 · Cited by 1,102
Small-Molecule Inhibitors of Protein-Protein Interactions: Progressing toward the Reality
Arkin, M. R., Tang, Y., & Wells, J. A. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.09.001 · Cited by 1,065
Twenty years on: the impact of fragments on drug discovery
Erlanson, D. A., Fesik, S. W., Hubbard, R. E., Jahnke, W., & Jhoti, H. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.109 · Cited by 1,000
Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease
Dewey, F. E., Gusarova, V., Dunbar, R. L., O’Dushlaine, C., Schurmann, C., Gottesman, O., McCarthy, S., Van Hout, C. V., Bruse, S., Dansky, H. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612790 · Cited by 885
Maschmeyer, I., Lorenz, A. K., Schimek, K., Hasenberg, T., Ramme, A. P., Hübner, J., Lindner, M., Drewell, C., Bauer, S., Thomas, A., et al. (2015) · Lab on a Chip · doi:10.1039/c5lc00392j · Cited by 861
Trends in the exploitation of novel drug targets
Rask-Andersen, M., Almén, M. S., & Schiöth, H. B. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3478 · Cited by 853
Development of PI3K inhibitors: lessons learned from early clinical trials
Rodon, J., Dienstmann, R., Serra, V., & Tabernero, J. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.10 · Cited by 766
Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state
Patricelli, M. P., Janes, M. R., Li, L.-S., Hansen, R., Peters, U., Kessler, L. V., Chen, Y., Kucharski, J. M., Feng, J., Ely, T., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1105 · Cited by 759
Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
Pommier, Y., O’Connor, M. J., & de Bono, J. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf9246 · Cited by 739
Ballard, P., Yates, J. W. T., Yang, Z., Kim, D.-W., Yang, J. C.-H., Cantarini, M., Pickup, K., Jordan, A., Hickey, M., Grist, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0399 · Cited by 718
Morgan, P., Van Der Graaf, P. H., Arrowsmith, J., Feltner, D. E., Drummond, K. S., Wegner, C. D., & Street, S. D. A. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2011.12.020 · Cited by 692
Self-citationAllele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
Lito, P., Solomon, M., Li, L.-S., Hansen, R., & Rosen, N. (2016) · Science · doi:10.1126/science.aad6204 · Cited by 691
Small‐Molecule PROTACS: New Approaches to Protein Degradation
Toure, M., & Crews, C. M. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201507978 · Cited by 674
Jänne, P. A., Shaw, A. T., Pereira, J. R., Jeannin, G., Vansteenkiste, J., Barrios, C., Franke, F. A., Grinsted, L., Zazulina, V., Smith, P., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70489-8 · Cited by 655
Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design
Ostrem, J. M. L., & Shokat, K. M. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.139 · Cited by 641
Finlay, M. R. V., Anderton, M., Ashton, S., Ballard, P., Bethel, P. A., Box, M. R., Bradbury, R. H., Brown, S. J., Butterworth, S., Campbell, A., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500973a · Cited by 636
Self-citationDNA-encoded chemistry: enabling the deeper sampling of chemical space
Goodnow, R. A., Dumelin, C. E., & Keefe, A. D. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.213 · Cited by 621
Pluripotent stem cells in disease modelling and drug discovery
Avior, Y., Sagi, I., & Benvenisty, N. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2015.27 · Cited by 592
Ortega, H. G., Yancey, S. W., Mayer, B., Gunsoy, N. B., Keene, O. N., Bleecker, E. R., Brightling, C. E., & Pavord, I. D. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30031-5 · Cited by 559
Castro, M., Wenzel, S. E., Bleecker, E. R., Pizzichini, E., Kuna, P., Busse, W. W., Gossage, D. L., Ward, C. K., Wu, Y., Wang, B., et al. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70201-2 · Cited by 488
Targeting eosinophils in allergy, inflammation and beyond
Fulkerson, P. C., & Rothenberg, M. E. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3838 · Cited by 482
Hanania, N. A., Korenblat, P., Chapman, K. R., Bateman, E. D., Kopecky, P., Paggiaro, P., Yokoyama, A., Olsson, J., Gray, S., Holweg, C. T. J., et al. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30265-x · Cited by 469
Lalonde, R. L., Kowalski, K. G., Hutmacher, M. M., Ewy, W., Nichols, D. J., Milligan, P. A., Corrigan, B. W., Lockwood, P. A., Marshall, S. A., Benincosa, L. J., et al. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100235 · Cited by 452
Carbognin, L., Pilotto, S., Milella, M., Vaccaro, V., Brunelli, M., Caliò, A., Cuppone, F., Sperduti, I., Giannarelli, D., Chilosi, M., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0130142 · Cited by 447
Cornerstones of CRISPR–Cas in drug discovery and therapy
Fellmann, C., Gowen, B. G., Lin, P.-C., Doudna, J. A., & Corn, J. E. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.238 · Cited by 443
Multi-Organ toxicity demonstration in a functional human in vitro system composed of four organs
Oleaga, C., Bernabini, C., Smith, A. S. T., Srinivasan, B., Jackson, M., McLamb, W., Platt, V., Bridges, R., Cai, Y., Santhanam, N., et al. (2016) · Scientific Reports · doi:10.1038/srep20030 · Cited by 442
Amorim, S., Stathis, A., Gleeson, M., Iyengar, S., Magarotto, V., Leleu, X., Morschhauser, F., Karlin, L., Broussais, F., Rezai, K., et al. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(16)00021-1 · Cited by 417
Hanania, N. A., Noonan, M., Corren, J., Korenblat, P., Zheng, Y., Fischer, S. K., Cheu, M., Putnam, W. S., Murray, E., Scheerens, H., et al. (2015) · Thorax · doi:10.1136/thoraxjnl-2014-206719 · Cited by 381
How Beyond Rule of 5 Drugs and Clinical Candidates Bind to Their Targets
Doak, B. C., Zheng, J., Dobritzsch, D., & Kihlberg, J. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01286 · Cited by 335
Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury
Proctor, W. R., Foster, A. J., Vogt, J., Summers, C., Middleton, B., Pilling, M. A., Shienson, D., Kijanska, M., Ströbel, S., Kelm, J. M., et al. (2017) · Archives of Toxicology · doi:10.1007/s00204-017-2002-1 · Cited by 328
Self-citationEberlein, C. A., Stetson, D., Markovets, A. A., Al-Kadhimi, K. J., Lai, Z., Fisher, P. R., Meador, C. B., Spitzler, P., Ichihara, E., Ross, S. J., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3167 · Cited by 301
Existing and Emerging Technologies for Point-of-Care Testing.
John, A. S., & Price, C. P. (2014) · PubMed · Cited by 294
MET: a promising anticancer therapeutic target
Peters, S., & Adjei, A. A. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.71 · Cited by 280
When Quality Beats Quantity: Decision Theory, Drug Discovery, and the Reproducibility Crisis
Scannell, J. W., & Bosley, J. (2016) · PLOS ONE · doi:10.1371/journal.pone.0147215 · Cited by 279
Chemical Space of DNA-Encoded Libraries: Miniperspective
Franzini, R. M., & Randolph, C. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01874 · Cited by 271
Structural insight into allosteric modulation of protease-activated receptor 2
Cheng, R. K. Y., Fiez-Vandal, C., Schlenker, O., Edman, K., Aggeler, B., Brown, D. G., Brown, G. A., Cooke, R. M., Dumelin, C. E., Doré, A. S., et al. (2017) · Nature · doi:10.1038/nature22309 · Cited by 246
Self-citationBiology-Oriented Synthesis: Harnessing the Power of Evolution
van Hattum, H., & Waldmann, H. (2014) · Journal of the American Chemical Society · doi:10.1021/ja505861d · Cited by 245
Critical review of the role of HTS in drug discovery
Macarron, R. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.02.001 · Cited by 241
Rebuilding the R&D engine in big pharma.
Garnier, J.-P. (2008) · PubMed · Cited by 228
Padovan, E., Spagnoli, G. C., Ferrantini, M., & Heberer, M. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.71.4.669 · Cited by 225
Padovan, E., Spagnoli, G. C., Ferrantini, M., & Heberer, M. (2002) · PubMed · Cited by 216
Ross, S. J., Revenko, A. S., Hanson, L. L., Ellston, R., Staniszewska, A., Whalley, N., Pandey, S. K., Revill, M., Rooney, C., Buckett, L. K., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal5253 · Cited by 177
Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer
Choueiri, T. K., Plimack, E., Arkenau, H.-T., Jonasch, E., Heng, D. Y. C., Powles, T., Frigault, M. M., Clark, E. A., Handzel, A. A., Gardner, H., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.2967 · Cited by 177
Peripheral blood eosinophils: a surrogate marker for airway eosinophilia in stable COPD
Negewo, N., McDonald, V., Baines, K., Wark, P., Simpson, J., Jones, P., & Gibson, P. (2016) · International Journal of Chronic Obstructive Pulmonary Disease · doi:10.2147/copd.s100338 · Cited by 169
Robertson, N. J., Jazayeri, A., Errey, J. C., Baig, A. H., Hurrell, E., Zhukov, A., Langmead, C. J., Weir, M., & Marshall, F. H. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.07.001 · Cited by 163
AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies
Rhyasen, G. W., Hattersley, M. M., Yao, Y., Dulak, A., Wang, W., Petteruti, P., Dale, I. L., Boiko, S., Cheung, T., Zhang, J., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0141 · Cited by 162
De Savi, C., Bradbury, R. H., Rabow, A. A., Norman, R. A., de Almeida, C., Andrews, D. M., Ballard, P., Buttar, D., Callis, R. J., Currie, G. S., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00984 · Cited by 161
Biomarkers of Response to Akt Inhibitor MK-2206 in Breast Cancer
Sangai, T., Akcakanat, A., Chen, H., Tarco, E., Wu, Y., Do, K.-A., Miller, T. W., Arteaga, C. L., Mills, G. B., Gonzalez-Angulo, A. M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1141 · Cited by 158
High throughput screening technologies for ion channels
Yu, H.-B., Li, M., Wang, W., & Wang, X. (2015) · Acta Pharmacologica Sinica · doi:10.1038/aps.2015.108 · Cited by 145
Potent and Selective Inhibitors of MTH1 Probe Its Role in Cancer Cell Survival
Kettle, J. G., Alwan, H. A. J., Biśta, M., Breed, J., Davies, N. L., Eckersley, K., Fillery, S. M., Foote, K. M., Goodwin, L., Jones, D. R., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01760 · Cited by 132
Winter, J., Anderson, M., Blades, K., Brassington, C., Breeze, A. L., Chresta, C. M., Embrey, K. J., Fairley, G., Faulder, P., Finlay, M. R. V., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501660t · Cited by 127
Sanacora, G., Johnson, M. R., Khan, A., Atkinson, S. D., Riesenberg, R. R., Schronen, J. P., Burke, M. A., Zajecka, J. M., Barra, L., Su, H.-L., et al. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.224 · Cited by 120
Exploratory toxicology as an integrated part of drug discovery. Part I: Why and how
Hornberg, J. J., Laursen, M., Brenden, N., Persson, M., Thougaard, A., Toft, D. B., & Mow, T. J. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.12.008 · Cited by 118
Workflow and Metrics for Image Quality Control in Large-Scale High-Content Screens
Bray, M., Fraser, A. N., Hasaka, T. P., & Carpenter, A. E. (2011) · SLAS DISCOVERY · doi:10.1177/1087057111420292 · Cited by 116
Jones, H. M., Gardner, I. B., Collard, W. T., Stanley, P. J., Oxley, P., Hosea, N. A., Plowchalk, D., Gernhardt, S., Lin, J., Dickins, M., et al. (2011) · Clinical Pharmacokinetics · doi:10.2165/11539680-000000000-00000 · Cited by 110
Chemoproteomic approaches to drug target identification and drug profiling
Bantscheff, M., & Drewes, G. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.11.003 · Cited by 110
Pointon, A., Harmer, A. R., Dale, I. L., Abi‐Gerges, N., Bowes, J., Pollard, C. E., & Garside, H. (2014) · Toxicological Sciences · doi:10.1093/toxsci/kfu312 · Cited by 105
Kawamura, T., Kawatani, M., Muroi, M., Kondoh, Y., Futamura, Y., Aono, H., Tanaka, M., Honda, K., & Osada, H. (2016) · Scientific Reports · doi:10.1038/srep26521 · Cited by 103
Know your target, know your molecule
Bunnage, M. E., Gilbert, A. M., Jones, L. H., & Hett, E. C. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1813 · Cited by 101
Bradbury, R. H., Callis, R. J., Carr, G. R., Chen, H., Clark, E. A., Feron, L. J. L., Glossop, S. C., Graham, M. A., Hattersley, M. M., Jones, C., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00070 · Cited by 96
Novel Acoustic Loading of a Mass Spectrometer: Toward Next-Generation High-Throughput MS Screening
Sinclair, I., Stearns, R., Pringle, S. D., Wingfield, J. M., Datwani, S. S., Hall, E., Ghislain, L., Majlof, L., & Bachman, M. (2015) · SLAS TECHNOLOGY · doi:10.1177/2211068215619124 · Cited by 92
A decade of innovation in pharmaceutical R&D: the Chorus model
Owens, P. K., Raddad, E., Miller, J. W., Stille, J. R., Olovich, K. G., Smith, N. V., Jones, R. S., & Scherer, J. C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4497 · Cited by 83
Grime, K., Barton, P., & McGinnity, D. F. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300476z · Cited by 81
Does size matter in R&D productivity? If not, what does?
Ringel, M. S., Tollman, P., Hersch, G. L., & Schulze, U. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4164 · Cited by 79
Fidock, M. D., Souberbielle, B. E., Laxton, C. D., Rawal, J. K., Delpuech-Adams, O. E., Corey, T., Colman, P., Kumar, V., Cheng, J. B., Wright, K., et al. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.60 · Cited by 71
Self-citationKogej, T., Blomberg, N., Greasley, P. J., Mundt, S. M., Vainio, M. J., Schamberger, J., Schmidt, G. P., & Hüser, J. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.10.011 · Cited by 68
Model-based drug discovery: implementation and impact
Visser, S. A. G., Aurell, M., Jones, R. D. O., Schuck, V., Egnell, A., Peters, S. A., Brynne, L., Yates, J. W. T., Jansson‐Löfmark, R., Tan, B., et al. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.05.012 · Cited by 67
Marx, V. (2015) · Nature · doi:10.1038/524503a · Cited by 66
Flow Cytometry: Impact on Early Drug Discovery
Edwards, B. S., & Sklar, L. A. (2015) · SLAS DISCOVERY · doi:10.1177/1087057115578273 · Cited by 65
The right compound in the right assay at the right time: an integrated discovery DMPK strategy
Ballard, P. G., Brassil, P. J., Bui, K., Dolgos, H., Petersson, C., Tunek, A., & Webborn, P. J. H. (2012) · Drug Metabolism Reviews · doi:10.3109/03602532.2012.691099 · Cited by 64
Hultman, I., Vedin, C., Abrahamsson, A., Winiwarter, S., & Darnell, M. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00396 · Cited by 64
Decision‐making in early clinical drug development
Frewer, P., Mitchell, P., Watkins, C. L., & Matcham, J. (2016) · Pharmaceutical Statistics · doi:10.1002/pst.1746 · Cited by 60
Self-citationSecondary pharmacology: screening and interpretation of off-target activities – focus on translation
Whitebread, S., Dumotier, B. M., Armstrong, D., Fekete, A., Chen, S., Hartmann, A., Muller, P. Y., & Urbán, L. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.04.021 · Cited by 60
Prospective Predictions of Human Pharmacokinetics for Eighteen Compounds
Zhang, T., Heimbach, T., Lin, W., Zhang, J., & He, H. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24373 · Cited by 56
Omlin, A. G., Jones, R. J., van der Noll, R., Satoh, T., Niwakawa, M., Smith, S. A., Graham, J., Ong, M., Finkelman, R. D., Schellens, J. H. M., et al. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0235-5 · Cited by 56
Why is it hard to terminate failing projects in pharmaceutical R&D?
Peck, R., Lendrem, D. W., Grant, I., Lendrem, C., & Isaacs, J. D. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4725 · Cited by 55
Yates, J. W. T., Ashton, S. E., Cross, D. A. E., Mellor, M. J., Powell, S. J., & Ballard, P. G. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0142 · Cited by 53
Managing the Risk of CYP3A Induction in Drug Development: A Strategic Approach
Jones, B., Rollison, H. E., Johansson, S. A., Kanebratt, K. P., Lambert, C., Vishwanathan, K., & Andersson, T. B. (2016) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.072025 · Cited by 53
Vieta, E., Thase, M. E., Naber, D., D’Souza, B., Rancans, E., Lepola, U., Olausson, B., Szamosi, J., Wilson, E., Hosford, D., et al. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.12.008 · Cited by 43
Van den Bergh, A., Sinha, V., Gilissen, R., Straetemans, R., Wuyts, K., Morrison, D., Bijnens, L., & Mackie, C. (2011) · Clinical Pharmacokinetics · doi:10.2165/11587230-000000000-00000 · Cited by 33
Modeling and Simulation Approaches for Cardiovascular Function and Their Role in Safety Assessment
Collins, T., Bergenholm, L., Abdulla, T., Yates, J. W. T., Evans, N. D., Chappell, M., & Mettetal, J. T. (2015) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.18 · Cited by 30
Self-citationTowards a hit for every target
Rees, S., Gribbon, P. M., Birmingham, K. E., Janzen, W. P., & Pairaudeau, G. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.19 · Cited by 29
Self-citationAn analytical comparison between point-of-care uric acid testing meters
Paraskos, J., Berke, Z., Cook, J., Miner, J. N., Braddock, M., Platt, A., & Hughes, G. (2015) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2016.1134326 · Cited by 28
Greiff, L., Ahlström‐Emanuelsson, C., Alenäs, M., Almqvist, G., Andersson, M., Cervin, A., Dolata, J., Lindgren, S., Mårtensson, A., Young, B., et al. (2015) · Inflammation Research · doi:10.1007/s00011-015-0873-2 · Cited by 27
Evolution of ADME Science: Where Else Can Modeling and Simulation Contribute?
Smith, D. A. (2013) · Molecular Pharmaceutics · doi:10.1021/mp3005319 · Cited by 25
Collins, T., Hattersley, M. M., Yates, J. W. T., Clark, E. A., Mondal, M., & Mettetal, J. T. (2017) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12194 · Cited by 25
Self-citationHigh‐Throughput RT‐PCR for Small‐Molecule Screening Assays
Bittker, J. A. (2012) · Current Protocols in Chemical Biology · doi:10.1002/9780470559277.ch110204 · Cited by 24
Reducing the risk of failure: biomarker-guided trial design
Townsend, M. J., & Arron, J. R. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.124 · Cited by 21
Jenkins, S., Yang, J., Ramalingam, S., Yu, K., Patel, S., Weston, S., Lawrance, R., Cantarini, M., Jänne, P., & Mitsudomi, T. (2016) · Journal of Thoracic Oncology · doi:10.1016/s1556-0864(16)30327-6 · Cited by 20
Horner, S., Robinson, S., Lees, D., Callander, R. D., & Roberts, R. A. (2014) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2014.07.008 · Cited by 16
The Rise of Systems Pharmacology in Drug Discovery and Development
Benson, N., & van der Graaf, P. H. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.14.66 · Cited by 16
Cited by
Applications of machine learning in drug discovery and development
Vamathevan, J., Clark, D., Czodrowski, P., Dunham, I., Ferran, E., Lee, G., Li, B., Madabhushi, A., Shah, P., Spitzer, M., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0024-5 · Cited by 3,228
Trends in kinase drug discovery: targets, indications and inhibitor design
Attwood, M. M., Fabbro, D., Sokolov, A. V., Knapp, S., & Schiöth, H. B. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00252-y · Cited by 779
Alzheimer's disease drug development pipeline: 2018
Cummings, J., Lee, G., Ritter, A., & Zhong, K. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.03.009 · Cited by 697
Davis, K. D., Aghaeepour, N., Ahn, A. H., Angst, M. S., Borsook, D., Brenton, A., Burczynski, M. E., Crean, C., Edwards, R., Gaudilliere, B., et al. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0362-2 · Cited by 496
Alzheimer’s disease drug development pipeline: 2023
Cummings, J., Zhou, Y., Lee, G., Zhong, K., Fonseca, J., & Cheng, F. (2023) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12385 · Cited by 477
Metadata
- Authors
- Morgan, P., Brown, D. G., Lennard, S., Anderton, M. J., Barrett, J. C., Eriksson, U., Fidock, M., Hamrén, B., Johnson, A., March, R. E., Matcham, J., Mettetal, J., Nicholls, D. J., Platz, S., Rees, S., Snowden, M. A., & Pangalos, M. N.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2018-01-19
- Volume
- 17
- Issue
- 3
- Pages
- 167-181
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2783569768
- Cited by
- 452
- References
- 113
- FWCI
- 3.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.